



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/43, 9/16, 9/46	A1	(11) International Publication Number: WO 91/16893 (43) International Publication Date: 14 November 1991 (14.11.91)
(21) International Application Number: PCT/GB91/00637 (22) International Filing Date: 22 April 1991 (22.04.91) (30) Priority data: 9009473.1 27 April 1990 (27.04.90) GB (71) Applicant (for all designated States except US): BEECHAM GROUP PLC [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : GRIMMETT, Francis, Walter [GB/GB]; DAVIDSON, Nigel, Philip [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB).		(74) Agents: WALKER, Ralph, Francis et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL FORMULATION (57) Abstract A pharmaceutical formulation comprises a medicament and an effervescent couple, plus optionally other excipients. Preferred medicaments are antibiotics, together with a citric acid - sodium bicarbonate couple. The formulation is provided for make up with water into an antibiotic suspension.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

PHARMACEUTICAL FORMULATION

This invention relates to pharmaceutical compositions for oral administration of antibiotics and other medicaments with unpleasant taste characteristics, and particularly to compositions formulated for dispersion in water prior to administration.

From the point of view of bioavailability, the preferred form of administration of sparingly soluble medicaments such as β -lactam antibiotics is often an aqueous suspension. However, there are problems associated with this form of administration. For example, such preparations in multidose form may have a limited shelf life, and usual methods of dose measurement lack accuracy.

Single dose powders for reconstitution in sachet form offer the advantages of suspensions without the problems of instability and measuring inaccuracy. Unfortunately, in the case of β -lactam antibiotics the problem of the unpleasant taste of these medicaments remains with such powder formulations.

Accordingly the present invention provides a pharmaceutical formulation, being a granular product containing a medicament and an effervescent couple which comprises a basic ingredient and an acidic ingredient, the basic ingredient liberating carbon dioxide when it and the acidic ingredient are contacted with water, which disperses in water to produce a suspension which can be swallowed by a patient.

It has been found that the inclusion of an effervescent couple in pharmaceutical granules can enable very rapid formation (eg 10-30 seconds) of a suspension in a small volume of water for a relatively low fill weight presentation, in comparison to traditional sachet

-2-

presentations of β -lactam antibiotics, without recourse to the use of additional disintegrating agents. The resulting suspension is found to be highly palatable and can consequently easily be swallowed by a patient.

5

Such sachet presentations are thus well-accepted by patients, especially small children and other groups of patients who may otherwise find the medicine difficult to take and who might otherwise refuse treatment. In addition
10 there are commercial advantages of such a presentation. For example, a low weight product reduces raw material costs, enables more unit doses per batch and simplifies the manufacturing and packaging processes. The granular product of the invention also has good flow characteristics which
15 result in improved sachet filling performance, ensuring that sachets may be well sealed.

Preferred medicaments are β -lactam antibiotics such as penicillins and cephalosporins, especially amoxycillin and
20 ampicillin preferably, amoxycillin trihydrate. A preferred β -lactamase inhibitor is clavulanic acid, preferably as potassium clavulanate. Typically, the ratio of antibiotic to inhibitor is 4:1 or 2:1 by weight, but ratios of 12:1 to 1:1 may be used. The weight of the antibiotic in a unit
25 dose may range from 125mg to 3g, expressed in terms of the activity of the antibiotic. The weight of antibiotic in the formulation, calculated as the free acid, may range from 5% to 50% preferably 40% to 50% based on the weight of the formulation.

30

The effervescent couple typically comprises citric acid or sodium hydrogen citrate and sodium bicarbonate, but other physiologically acceptable and/alkaline or alkaline earth metal carbonate mixtures may be used, for example tartaric,
35 adipic, fumaric or malic acids, and sodium, potassium or calcium bicarbonates or sodium glycine carbonate.

-3-

The weight of acidic ingredient may be in the range 0.5% to 20%, eg 1.0% to 10%, preferably 1.5% to 5%, of the weight of the formulation.

5

The weight of the basic component may be in the range 0.5% to 30%, eg 1.0 to 20%, preferably 1.5% to 10%, of the weight of the mixture.

10 The granular formulation may contain any of the conventional excipients such as diluents/fillers/bulking agents used in pharmaceutical products, for example lactose, fructose, mannitol or sorbitol alone or in combination eg making up 0.1% to 60%, typically 30% to 50% by weight of the
15 formulation. Other conventional excipients may include lubricants eg making up 0.1% to 3%, typically 0.25% to 2.5% by weight of the formulation such as magnesium stearate, sweetening agents such as sugars sodium saccharin and aspartame eg making up 0.1% to 2% by weight and flavouring
20 agents eg lemon and/or lime typically making up 0 to 20% by weight of the formulation. Multidose products for reconstitution may include suspending agents such as Xanthan gum eg Keltrol - Trade Mark, (a sodium, potassium or calcium salt of a partially acetylated polysaccharide containing D
25 glucose, D mannose and D glucuronic acid units). Alternative thickeners are hydroxypropyl methyl celluloses or hydroxypropyl cellulose (eg Klucel - Trade Mark), sodium carboxymethyl - cellulose - carmellose or aerosil. Typically such suspending agents may be present at 1% to 5%
30 by weight. Multidose products may also include preservatives such as sodium benzoate, typically at 0.2% to 1.5% by weight. A desiccant such as syloid (Trade Mark) may also be included for moisture sensitive antibiotics.

35 The invention also provides a process for the preparation of such a pharmaceutical formulation, comprising admixing the medicament and the effervescent couple, and subsequently compacting the mixture into a granular product.

-4-

A preferred size fraction for the granular formulation of the invention is less than 1000μ , eg 30μ to 600μ , particularly 100μ to 425μ . To prepare the granular formulation of the invention the starting components, especially the medicament are preferably finely milled to a particle size of less than 200μ , to result in a particle size of typically $<30\mu$ - 200μ . Starting materials of $<30\mu$ - 1000μ (with the exception of the medicament) may be used.

10 The coarse excipient fraction may improve flow and hence will aid the compaction process.

Typically the manufacturing process involves the following stages:

15

- (a) Mill the medicament finely at fast speed, through a 0.020 inch (0.5mm) screen.
- (b) Mill the diluent/filler/bulking agent and sweeteners at
20 slow speed through an 0.040 (1.0mm) inch screen.
- (c) Sieve through a 20 mesh screen the flavours, effervescent couple components and magnesium stearate.
- 25 (d) Blend the components and compress the mix on a tableting or slugging machine to give compacts (slugs) of medium density or roller compact the mix to a medium pressure and product density.
- 30 (e) Pass the compacted material through a mill at low speed fitted with a screen, to form granules.
- (f) Sieve the granules and collect the desired size fraction. Recycle the coarser and finer material to
35 the compaction equipment if it is desired to limit the

-5-

size range of the granule.

(g) Fill or tablet the granule under low humidity cover.

5 Preferably the entire process (a) to (g) is carried out under a low humidity, eg <30% RH and a low temperature eg 10-25°C. Preferably the components are used anhydrous or substantially anhydrous.

10 The granular formulation may be coated with an acid soluble polymer to assist rapid and widespread release of the medicament to occur in the stomach, or they may be coated with an enteric (acid resistant polymer) to assist rapid release in the intestine. Suitable acid soluble polymers
15 include Eudragit E (Trade Mark) - a cationic polymer synthesised from dimethylaminoethyl methacrylate, ethylcellulose or ethylcellulose mixtures with water soluble polymers such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose.

20

The granules are preferably packed in conventional unit dose sachets, eg composed of a laminate of polymer, paper and foil. A common granular formulation may be used at a range of different fill weights to provide a range of unit doses
25 eg 125 mg, 250 mg, 500 mg, 1g and 3g of amoxycillin.

Alternatively the granular formulation may be provided in jars etc as a multidose presentation for make up in water.

Alternatively the granular formulation may be tabletted, eg
30 by a process of compaction to provide a tablet formulation. Such tablets may each contain a unit dose (as described above) of the medicament and may be provided for administration by swallowing, dispersal in water then swallowing, or as coated pessary or rectal tablets for human
35 or animal patients. The formulation of the invention therefore has a further advantage in providing a common

-6-

material for administration in sachets or as tablets.

The invention also provides a process for the use of a pharmaceutical formulation as described above in the manufacture of a medicament for the treatment of bacterial infections.

The invention also provides a method of treatment of bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of a pharmaceutical formulation as described above.

The invention also provides a pharmaceutical formulation as described above for use in the treatment of bacterial infections.

The invention is illustrated by the following Example.

-7-

Example 1250mg. Dose Fizzy Granule (β -lactam antibiotic)

5	<u>Ingredients</u>	<u>mg/sachet</u>	<u>(% w/w)</u>
	Amoxycillin Trihydrate equivalent to Amoxycillin free acid	250.00	41.667
10	Magnesium stearate	6.75	1.125
	Citric acid	12.50	2.083
15	Sodium bicarbonate	25.00	4.167
	Sodium saccharin	2.50	0.417
	Lemon dry flavour	27.50	4.583
20	Lime dry flavour	1.38	0.230
	Sorbitol B.P.	90.00	15.000
25	Mannitol U.S.P.	184.37	30.72
	<u>Total.</u>	<u>600 mg</u>	<u>100.00</u>

30 (all of the above ingredients were used in a substantially anhydrous state).

Manufacturing Procedure for Example 1

35 The amoxycillin was first milled finely at a high speed through an 0.02 inch (0.5mm) screen. Then the mannitol and sodium saccharin were milled at a slow speed through an 0.04 inch (1mm) screen. The flavours, citric acid, sodium bicarbonate and magnesium stearate were then sieved through
 40 a 20 mesh sieve. The mixture was compressed on a rotary tableting machine to give compacts of density 0.39-0.40.

-8-

The compacted material was then milled at low speed, 1750 rpm, with knives forward and fitted with an 0.097 inch (0.25mm) screen. The granules were sieved on a 20 mesh overlying an 80 mesh screen and the 20 - 80 fraction was collected. This granular product could then be filled into containers or sachets, or tabletted in a conventional manner. The procedure was performed in a humidity of 30% RH or less, at 10-25°C.

- 10 Alternative fruity or citrus flavours could be used in the formulation of example 1. Furthermore the quoted percentages could be varied by $\pm 10\%$ without any significant effect on the properties of the formulation.
- 15 The quantities of ingredients quoted in example 1 are for a 250mg unit dose amoxycillin formulation. By simply increasing or decreasing the quoted quantities in direct proportion formulations for unit doses of other weights of amoxycillin can be made up.

CLAIMS (A)

1. A pharmaceutical formulation, being a granular product containing a medicament and an effervescent couple which comprises a basic ingredient and an acidic ingredient, the basic ingredient liberating carbon dioxide when it and the acidic ingredient are contacted with water.
2. A formulation according to claim 1 wherein the medicament is a β -lactam antibiotic.
3. A formulation according to claim 2 wherein the antibiotic is amoxycillin.
4. A formulation according to claim 2 or 3 containing 5% to 50% by weight of the antibiotic.
5. A formulation according to claim 4 containing 40% to 50% by weight of the antibiotic.
6. A formulation according to any one of preceding claims 1 to 5 wherein the effervescent couple comprises citric acid or sodium hydrogen citrate and sodium bicarbonate.
7. A formulation according to any one of preceding claims 1 to 5 wherein the acidic ingredient is selected from tartaric, adipic, fumaric or malic acid, and the basic ingredient is selected from sodium, potassium or calcium bicarbonate or sodium glycine carbonate.
8. A formulation according to any one of preceding claims 1 to 7 wherein the acidic ingredient is present in the range 0.5% to 20% of the weight of the formulation.

10

9. A formulation according to claim 8 wherein the acidic ingredient is present in the range 1% to 10% of the weight of the formulation.
10. A formulation according to any one of preceding claims 1 to 9 wherein the basic ingredient is present in the range 0.5% to 30% of the weight of the formulation.
11. A formulation according to any one of preceding claims 1 to 10 wherein the size of the granular product is in the range 30 to 600 μ .
12. A formulation according to claim 11 wherein the size of the granular product is in the range 100 to 425 μ .
13. A formulation according to any one of preceding claims 1 to 12 having a composition within $\pm 10\%$ of the following:

Amoxycillin trihydrate	
equivalent to amoxycillin	
free acid	41.667 wt %
Magnesium stearate	1.125 wt %
Citric acid	2.083 wt %
Sodium bicarbonate	4.167 wt %
Sodium saccharin	0.417 wt %
Lemon dry flavour	4.583 wt %
Lime dry flavour	0.230 wt %
Sorbitol BP	15.000 wt %
Mannitol USP	30.720 wt %

14. A process for the preparation of a pharmaceutical formulation as claimed in any one of preceding claims 1 to 13 comprising admixing a medicament and an effervescent couple and subsequently compacting the mixture into a granular product.

11

15. A process for preparing a pharmaceutical tablet formulation which comprises compacting a granular product as claimed in any one of preceding claims 1 to 13 into a tablet.

16. A tablet formulation being the product of a process as claimed in claim 15.

17. A process for the use of a pharmaceutical formulation as claimed in any one of preceding claims 1 to 13 or 16 for the manufacture of a medicament for the treatment of bacterial infections.

18. A pharmaceutical formulation as claimed in any one of preceding claims 1 to 13 or 16 for use in the treatment of bacterial infections.

19. A method of treatment of bacterial infections in human or animal patients which comprises the administration of a therapeutically effective amount of a pharmaceutical formulation as claimed in any one of preceding claims 1 to 13 or 16.

INTERNATIONAL SEARCH REPORT

International Application No **PCT/GB 91/00637**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 31/43, A 61 K 9/16, A 61 K 9/46														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top;">IPC⁵</td> <td style="padding: 5px; vertical-align: top;">A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	A 61 K								
Classification System	Classification Symbols													
IPC ⁵	A 61 K													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ¹⁰</th> <th style="border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 15%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> GB, A, 1300998 (BIOCHEMIE) 29 December 1972 see claims; page 2, lines 30-50, 66-70 -- </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-2, 6, 15-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> US, A, 4888177 (G. GERGELY) 19 December 1989 see claims 1, 3, 10-12, 15, 22, 28 -- </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-3, 6-7, 14-17</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P, X</td> <td style="padding: 5px;"> EP, A, 0396335 (BEECHAM) 7 November 1990 see claims 1-2, 4-5, 7-9, 14-16; page 2, lines 50-51, 54-55; page 3, lines 11-13, 18-21, 45-47; page 4, example 1; page 4, lines 45-47 ----- </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-10, 13-18</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	GB, A, 1300998 (BIOCHEMIE) 29 December 1972 see claims; page 2, lines 30-50, 66-70 --	1-2, 6, 15-16	A	US, A, 4888177 (G. GERGELY) 19 December 1989 see claims 1, 3, 10-12, 15, 22, 28 --	1-3, 6-7, 14-17	P, X	EP, A, 0396335 (BEECHAM) 7 November 1990 see claims 1-2, 4-5, 7-9, 14-16; page 2, lines 50-51, 54-55; page 3, lines 11-13, 18-21, 45-47; page 4, example 1; page 4, lines 45-47 -----	1-10, 13-18
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	GB, A, 1300998 (BIOCHEMIE) 29 December 1972 see claims; page 2, lines 30-50, 66-70 --	1-2, 6, 15-16												
A	US, A, 4888177 (G. GERGELY) 19 December 1989 see claims 1, 3, 10-12, 15, 22, 28 --	1-3, 6-7, 14-17												
P, X	EP, A, 0396335 (BEECHAM) 7 November 1990 see claims 1-2, 4-5, 7-9, 14-16; page 2, lines 50-51, 54-55; page 3, lines 11-13, 18-21, 45-47; page 4, example 1; page 4, lines 45-47 -----	1-10, 13-18												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">8th July 1991</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">02.09.91</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;"> Danielle van der Haas </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">8th July 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center;">02.09.91</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> Danielle van der Haas </div>								
Date of the Actual Completion of the International Search <div style="text-align: center;">8th July 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center;">02.09.91</div>													
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> Danielle van der Haas </div>													

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 19, because they relate to subject matter not required to be searched by this Authority, namely:

Please see rule 39.1(iv) - PCT:
Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.